 |
Humanized anti-tac |
|---|---|
| Trade Name | Zenapax |
| Orphan Indication | Prevention of acute graft-vs-host disease following bone marrow transplantation |
| USA Market Approval | USA |
| USA Designation Date | 1993-03-05 00:00:00 |
| Sponsor | Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07110 |
